MétaCan
Menu
Back to cohort
Record W2207297826 · doi:10.1002/eji.201546005

Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

2015· article· en· W2207297826 on OpenAlexfundno aff
Susanne M. Cabrera, Xujing Wang, Yi‐Guang Chen, Shuang Jia, Mary L. Kaldunski, Carla J. Greenbaum, Thomas Mandrup‐Poulsen, Martin J. Hessner

Bibliographic record

VenueEuropean Journal of Immunology · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicDiabetes and associated disorders
Canadian institutionsnot available
FundersEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Child Health and Human DevelopmentNational Institute of Diabetes and Digestive and Kidney DiseasesEuskal Herriko UnibertsitateaNational Institutes of HealthTechnische Universität MünchenNovo NordiskYale UniversityUniversity of TorontoVarsinais-Suomen SairaanhoitopiiriNational Center for Advancing Translational SciencesJoslin Diabetes CenterLeids Universitair Medisch CentrumUniversität UlmUniversiteit LeidenUniversity of BristolCedars-Sinai Medical CenterU.S. National Library of MedicineUniversity of PittsburghUniversity of MinnesotaUniversity of MiamiVanderbilt UniversityGeorge Washington UniversityUniversity of South FloridaNational Center for Research ResourcesNational Institute of Allergy and Infectious DiseasesAmerican Diabetes AssociationUniversity of WashingtonJuvenile Diabetes Research Foundation International
KeywordsCanakinumabMedicineAntagonismClinical trialImmune systemInflammationImmunologyInterleukinInternal medicineCytokineClinical endpointPharmacologyOncologyBioinformaticsDiseaseReceptorBiology

Abstract

fetched live from OpenAlex

It was hypothesized that IL-1 antagonism would preserve β-cell function in new onset Type 1 diabetes (T1D). However, the Anti-Interleukin-1 in Diabetes Action (AIDA) and TrialNet Canakinumab (TN-14) trials failed to show efficacy of IL-1 receptor antagonist (IL-1Ra) or canakinumab, as measured by stimulated C-peptide response. Additional measures are needed to define immune state changes associated with therapeutic responses. Here, we studied these trial participants with plasma-induced transcriptional analysis. In blinded analyses, 70.2% of AIDA and 68.9% of TN-14 participants were correctly called to their treatment arm. While the transcriptional signatures from the two trials were distinct, both therapies achieved varying immunomodulation consistent with IL-1 inhibition. On average, IL-1 antagonism resulted in modest normalization relative to healthy controls. At endpoint, signatures were quantified using a gene ontology-based inflammatory index, and an inverse relationship was observed between measured inflammation and stimulated C-peptide response in IL-1Ra- and canakinumab-treated patients. Cytokine neutralization studies showed that IL-1α and IL-1β additively contribute to the T1D inflammatory state. Finally, analyses of baseline signatures were indicative of later therapeutic response. Despite the absence of clinical efficacy by IL-1 antagonist therapy, transcriptional analysis detected immunomodulation and may yield new insight when applied to other clinical trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.004
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.498
Threshold uncertainty score0.478

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0040.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.292
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations58
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of ImmunologySame topicDiabetes and associated disordersFrench-language works237,207